Home LiteratureArticle Details
PMID: 8507558 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

P19 embryonal carcinoma cells.

The International journal of developmental biology ·Vol. 37 ·No. 1 ·1993-03-00 ·Pages 135-40

McBurney MW

Abstract

P19 cells are a line of pluripotent embryonal carcinoma able to grow continuously in serum-supplemented media. The differentiation of these cells can be controlled by nontoxic drugs. Retinoic acid effectively induces the development of neurons, astroglia and microglia--cell types normally derived from the neuroectoderm. Aggregates of P19 cells exposed to dimethyl sulfoxide differentiate into endodermal and mesodermal derivatives including cardiac and skeletal muscle. P19 cells can be effectively transfected with DNA encoding recombinant genes and stable lines expressing these genes can be readily isolated. These manipulations make P19 cells suitable material for investigating the molecular mechanisms governing developmental decision made by differentiating pluripotent cells.

MeSH Terms
Animals Cell Differentiation/drug effects,genetics Dimethyl Sulfoxide/pharmacology Dose-Response Relationship, Drug Ectoderm Mesoderm Mice Teratoma/genetics,pathology Transfection Tretinoin/pharmacology
Chemicals
Tretinoin Dimethyl Sulfoxide
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
McBurney M W
Department of Medicine, University of Ottawa, Ontario, Canada.
Article Info
Journal
The International journal of developmental biology
Abbr.
Int J Dev Biol
ISSN
0214-6282
Published
1993-03-00
Pages
135-40
Language
English
Region
Spain
NLM ID
8917470
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]